Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237678 · ClinicalTrials.gov registry record · Phase 1
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
A Phase 1 study, sponsored by ImmunoGen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 181
- Enrollment target
NCT01237678: Clinical Trial Phase 1 study, sponsored by ImmunoGen.
NCT01237678 is a Phase 1 study that was terminated before completion, run by ImmunoGen. The registered enrollment target is 181 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (202% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01237678, a Phase 1 study, was terminated before completion, sponsored by ImmunoGen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Primary Outcome
The primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) and characterize the dose limiting toxicities (DLT) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. For the purposes of dose escalation and determination of MTD, DLTs were defined as AEs or abnormal laboratory values related to study treatment which occurred in Cycle 1 of the Dose Escalation phase, including any AEs
Interventions
- DRUG IMGN901
- DRUG Carboplatin and Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Why NCT01237678 stopped before completion
NCT01237678 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (202% higher).
The record links to 0 conditions, and to 2 interventions - of which IMGN901 is the first listed.
NCT01237678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01237678 about?
NCT01237678 is a clinical study titled "A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer". The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
What is the current status of trial NCT01237678?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 181 participants. The study started on 2010-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01237678?
The interventions under investigation include: IMGN901 (DRUG), Carboplatin and Etoposide (DRUG).
Who is sponsoring clinical trial NCT01237678?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01237678's enrollment target sits among peer trials
181 299th of 2000 higher than 1,702 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia